Table 3.

Prognostic Values of Top 10 ESPL1 Co-Expressed Genes in HCC Based on Our Cohort

Gene	Patients	OS
	(n=121)	No. of Events	HR (95% CI)	Adjusted Pa
ESPL1				0.033
Low	61	16	Ref
High	60	29	2.019 (1.058–3.852)
GTSE1				0.004
Low	61	13	Ref
High	60	32	2.732 (1.367–5.459)
KIF18B				0.055
Low	61	15	Ref
High	60	30	1.918 (0.987–3.729)
BUB1B				0.034
Low	61	15	Ref
High	60	30	2.009 (1.053–3.833)
GINS1				0.097
Low	61	16	Ref
High	60	29	1.723 (0.907–3.273)
PRC1				0.039
Low	61	15	Ref
High	60	30	1.982 (1.034–3.802)
KIF23				0.027
Low	61	14	Ref
High	60	31	2.119 (1.090–4.120)
KIF18A				0.116
Low	61	16	Ref
High	60	29	1.687 (0.879–3.237)
TOP2A				0.001
Low	61	12	Ref
High	60	33	3.124 (1.547–6.308)
NEK2				0.136
Low	61	16	Ref
High	60	29	1.626 (0.858–3.080)

Note: ^aAdjusted P, adjustment for BCLC stage, Edmondson grade, age, tumor size and AFP.

Abbreviations: ESPL1, extra spindle pole bodies-like 1; GTSE1, genes G-2 and S-phase expressed 1; KIF18B, kinesin family member 18B; BUB1B, mitotic checkpoint serine/threonine kinase B; GINS1, GINS complex subunit 1; PRC1, protein regulator of cytokinesis 1; KIF23, kinesin family member 23; KIF18A, TOP2A, DNA topoisomerase II alpha; NEK2, NIMA related kinase 2.